Ophthalmic diagnostic device manufacturer ObjectiVision has made its final pitch to the Federal Court at the end of trial in a long-running intellectual property and contract dispute with the University of Sydney, saying in closing submissions that the school had run a “curious” case.
Generic drug maker Alphapharm is fighting a bid by global pharmaceutical giant Sanofi-Aventis to block the listing of one of its injector pens, saying the proposed injunction should be denied because Sanofi is seeking to amend the patent at issue.
A maker of guard rails used on highways has won a judgment invalidating a rival’s patent, with a judge finding the patent lacks novelty.
A Copyright Tribunal decision that led to substantially lower sound recording licence fees for Foxtel was “beyond the pale” because it compared fees charged to the cable TV giant with those charged to fitness centres, the Full Federal Court heard Wednesday.
Ophthalmic diagnostic device manufacture ObjectiVision can’t file amended claims for damages following a trial in a copyright and contract case against the University of Sydney, with a judge saying the school would be “severely prejudiced” if the new claims were allowed.
Ophthalmic diagnostic device maker ObjectiVision’s amended claims for damages, filed after a 25-day patent hearing, are “outlandish” and “unfair,” the University of Sydney has told the Federal Court.
Industrial filter manufacturer Vokes has lost its fight to correct a 17-year-old error that removed it as the registered owner of six trade marks, with the Full Federal Court ruling Monday that the Registrar did not have the power to fix the mistake of her own initiative.
Australian drug company Homart Pharmaceuticals has lost an appeal of a ruling that found the packaging of its bio-placenta skin care oil was intentionally and deceptively similar to a rival’s get-up, in breach of the consumer law.
A serviced apartments provider wants to appeal a ruling that blocked it from trade marking the phrase “Waldorf Apartment” after Hilton Worldwide — which owns New York’s iconic Waldorf Astoria hotel – opposed the move.
A lawyer for the University of Sydney has attacked ObjectiVision for failing to produce any commercial benefits from the glaucoma detection method at the centre of a patent infringement dispute, despite holding exclusive rights to the technology for 11 years.